I like to think about technology and how it can improve our health and our sustainable future.

 

 

I was previously a healthcare investor at Bain Capital. Prior to that, I worked at Blackstone on European financial restructuring and at Goldman Sachs and the World Health Organization. My work has been published in Science, JAMA, and the New England Journal of Medicine and cited by the Wall Street Journal, Washington Post, and Le Figaro. I graduated from Harvard, where I studied Biomedicine.


The empirical findings of this study raise interesting issues about the future of drug development . . .
— Dr. Robert Califf, Commissioner of the FDA, et al.

Antibiotic Innovation

 Cumulative incidence curves for progression to subsequent phase shown for antibiotics (blue) and non-antibiotic drugs (black). Source: Hwang TJ, et al.  Science  2014; 344: 967-969.

Cumulative incidence curves for progression to subsequent phase shown for antibiotics (blue) and non-antibiotic drugs (black). Source: Hwang TJ, et al. Science 2014; 344: 967-969.

Our paper in Science quantifies risks in antibiotic research and development. To assess differential probabilities of success, we merged individual compound data from 1990 to 2012 and fit our data to accelerated failure time models (continued in blog post, Science article)


Posts